Molecular and Diagnostic Research Lab-4, Department of Cancer Biology, The Gujarat Cancer & Research Institute, Ahmedabad, India.
J Egypt Natl Canc Inst. 2022 May 2;34(1):19. doi: 10.1186/s43046-022-00120-9.
Breast cancer is a fatal disease and a major reason of cancer associated death in females. Many factors along with miRNA are responsible for the development and the progression of the disease. The miRNA plays a very crucial role in the regulation of the genes. MicroRNAs are of three major types-oncomiRs, tumor suppressive miRNAs, and metastamiRs.
MicoRNA-10b is a prometastatic microRNA targeting various genes that facilitates multiple outcomes such as metastasis, increased capacity for invasion, proliferation and migration, increased epithelial-mesenchymal transformation, angiogenesis, and therefore exhibits worse clinical outcomes. It is found to be upregulated in various malignancies and is thus to be considered as the possible therapeutic candidate.
The therapeutic delivery of miR-10b antagonists (antagomiRs) and/or knockdown of miRNA is beneficial in reducing tumor growth. Additionally, combination therapy which includes antisense oligonucleotides using miR-10b can function as an effective approach to tumor regression and drug resistance reversal.
乳腺癌是一种致命的疾病，也是女性癌症相关死亡的主要原因。许多因素与 miRNA 一起导致了疾病的发生和发展。miRNA 在基因调控中起着至关重要的作用。miRNA 主要有三种类型：致癌 miRNA、肿瘤抑制 miRNA 和转移促进 miRNA。
miRNA-10b 是一种促转移 miRNA，针对多种基因，促进多种结果，如转移、侵袭能力增强、增殖和迁移、上皮-间充质转化增加、血管生成，因此表现出更差的临床结果。它在各种恶性肿瘤中上调，因此被认为是可能的治疗候选物。
miR-10b 拮抗剂（antagomiRs）的治疗性递送和/或 miRNA 的敲低有助于减少肿瘤生长。此外，包括使用 miR-10b 的反义寡核苷酸的联合治疗可以作为肿瘤消退和逆转耐药性的有效方法。
